

Date of Revision: 04-28-2023

Name: **Albert Joseph Arias, M.D., M.S.**

Academic Appointment: Associate Professor of Psychiatry, with Tenure

Term: July 1, 2021 to June 30, 2024

School: Medical College of Virginia/Virginia Commonwealth University

EDUCATION

- Sept 1993 - June 1997** **B.S.** Michigan State University, East Lansing, MI
B.S. in Human Physiology with a Specialization in Health and Humanities Graduated with Honors in the Honors College
- Aug 1997 – May 2001** **M.D.** Michigan State University College of Human Medicine, East Lansing, MI
Doctor of Medicine
- Sept 2008 – June 2010** **M.S.** University of Connecticut (Health Center), Farmington, CT
Master’s Degree, Clinical and Translational Research,

CAREER/ACADEMIC APPOINTMENTS

- July 2001 – Apr 2002** Intern/Resident Physician in the Family Medicine/Psychiatry Double Board Program, University of Cincinnati-Health Alliance, Cincinnati, OH
- Aug 2002 – Feb 2006** Resident Physician, Department of Psychiatry, University of Connecticut Health Center, Farmington, CT
- Feb 2006 – Feb 2011** Assistant Professor, Department of Psychiatry, University of Connecticut School of Medicine, Farmington Connecticut
-Attending Psychiatrist
- Feb 2011- July 2016** **Assistant Professor**, Department of Psychiatry, Yale School of Medicine,
New Haven, CT
-2011-2012 Attending Psychiatrist, VACT Psychiatric Emergency Room
-2012 Attending Psychiatrist, VACT Outpatient Substance Abuse Clinic
- July 2016-July 2018** **Associate Professor**, Department of Psychiatry, Yale School of Medicine, New Haven, CT

Albert J. Arias, M.D., M.S.

July 2018-present **Associate Professor**, Department of Psychiatry, VCU Health/MCV

July 2021-present **Associate Professor with Tenure, VCU Psychiatry**

ADMINISTRATIVE POSITIONS

July 2009 - Oct 2010 University of Connecticut Health Center,
Director of Outpatient Addiction Psychiatry Clinic, Farmington, CT

July 2015 - June 2018 Co-director of the VA TeleSubstance Abuse Consultation Service,
part of the National Tele-Mental Health Center, a nation-wide
program servicing VA medical centers across the country

Jan 2016 – June 2018 Director of the Tele-addictions branch of the West Haven VAMC

July 2018 -present Associate Division Chair, Addiction Psychiatry, VCU/MCV

July 2018 – June 2019 Associate Training Director, VCU Addiction Medicine Fellowship

June 2019 – present Training Director, VCU Health Addiction Medicine Fellowship

June 2019 – Jan 2023 Medical Director, VCU Health Outpatient Addictions Clinic

BOARD CERTIFICATION

Aug 2007 Board Certified in Psychiatry, American Board of Psychiatry and
Neurology

Oct 2008 American Society of Addiction Medicine, Certified

Oct 2009 American Board of Addiction Medicine, Certified

Feb 2017 (Recertification) Board Certified in Psychiatry, ABPN

Feb 2019 Board Certified in Addiction Medicine, American Board of Preventive Medicine

PROFESSIONAL HONORS AND RECOGNITION

International/National/Regional

May 2023 President, Psychiatric Society of Virginia (APA district branch)

May 2022 President Elect, Psychiatric Society of Virginia (APA district branch)

- Dec 2021 Elected, Full Member of the American College of Neuropsychopharmacology
- Dec 2016 Elected, Associate Member of the American College of Neuropsychopharmacology
- Dec 2009 American College of Neuropsychopharmacology, Research Travel Award for Minorities
- June 2008 American Psychiatric Association Research Colloquium for Junior Investigators
- Dec 2005 American Academy of Addiction Psychiatry Research Award (for resident, fellow, and early-career level investigators)
- Aug 1993 Finalist for the MSU Spartan Scholarship Competition (received a full scholarship based on achievement and need)

GRANT/CLINICAL TRIALS HISTORY:

A) Current Grants

Agency: NIDA
I.D.#: 1UG1 DA050207
Title: Laboratories For Early Clinical Evaluation Of Pharmacotherapies For Substance Use Disorders.
P.I.: Moeller (Contact PI), Arias (Co-PI)
Role: Co-PI
Percent Effort: 15%
Total Costs for project period: \$3,046,000
Project Period: 05/01/20-4/30/2025

I.D.#: T25HP37629
Agency: HRSA
Title: The VCU Health Addiction Medicine Fellowship Expansion Program
P.I.: Arias
Role: PI
Percent Effort: 20%
Total Costs: ~\$3,000,000
Project Period: 7/1/2020-6/30/2025

Agency: VCU internal award (Value and Efficiency Teaching and Research Award)
I.D.#: None
Title: Predicting Relapse and Providing Timely Interventions in Patients with Alcohol-Related Liver Disease
P.I.: Albert Arias, M.D., Vimal Mishra MD, Arun Sanyal MD (Co-PIs)

Albert J. Arias, M.D., M.S.

Role on Project: PI (co-PI)
Percent Effort: 1%
Total costs for project period: \$65,000
Project period: 12/1/20-5/30/2022

Agency: Private Nonprofit; Foundation for Alcoholism Research
Title: Toward Improved Diagnosis and Precision Treatment of Alcohol Use Disorder:
Identifying the Neural Correlates of Key Alcohol Use Disorder Related Neurobehavioral
Phenotypes.
P.I.: Albert Arias, M.D.
Role on project: PI
Percent Effort: 1%
Direct costs per year: ~\$50,000
Total costs for project period: \$95,000
Project period: 11/1/19-12/31/2022 (renewed for ~\$40,000 Jan 2022)

NIDA
UG3 DA048768-01A1
Novel LAAM formulations to treat Opioid Use Disorder
PI: Xu
Role on Project: Co-Investigator
Percent Effort: 5%
Yearly total costs: \$636,639.50
Project period: 9/30/2019-8/31/22

AHRQ
R18 HS027077 0.6 calendar
Practice Facilitation to Promote Evidence-based Screening and Management of Unhealthy
Alcohol Use In Primary Care
PI: Krist
Role on Project: Co-Investigator
Percent effort: 5%
Total yearly costs: \$653,458
Project period: 9/1/2019-9/29/2022

NIH/NIDA
1UG3DA052282 9/1/2020 – 8/31/2022 0.60 calendar
NOP Receptor Antagonist for OUD Pharmacotherapy
(PI: Cunningham)
\$27,642
Role: Co-Investigator

B) Past Grants

Agency: NIAAA
I.D.#: R21AA026681
Title: "Perampanel Treatment of Alcohol Use Disorder"
P.I.: Albert Arias, M.D.
Role on Project: PI
Percent Effort: 10%
Direct costs per year: \$150,000
Total costs for project period: \$275,000
Project period: 10/1/18-9/30/2021 (NCE)

Agency: NIAAA
I.D.#: R01 AA024466
Title: "Zonisamide treatment of alcohol use disorder: an evaluation of efficacy and mechanism of action"
P.I.: Albert Arias, M.D.
Role on Project: PI
Percent Effort: 20%
Total costs for project period: ~\$2,800,000
Project period: 2/1/16-1/31/21 (**renewal pending**)...

VA Merit Award CSR&D
I.D.#: 1I01CX001012-01A2
Title: "Effectiveness of Zonisamide in Alcohol Dependent Veterans"
P.I.: Albert Arias, M.D., M.S.
Role: PI
Percent Effort: 3/8 VA, time as service demands allow
Direct costs per year: \$150,000
Total Costs per project period: \$750,000
Project Period: 10/01/2014-10/01/2018

Agency: NIDA
I.D.# : 1R43DA032178-01 (SBIR)
Title: "Saliva Analyzer for Diagnosing SRD Patient Drug Use" (Phase II)
P.I. Stuart Farquarson, Ph.D.
Role: Site PI
Percent Effort: 5%
Direct costs per year: avg. \$60,000 (Subaward)
Total Costs for project period: \$134,930 direct
Project Period: 7/15/14-7/15/16

Agency: NIAAA
I.D.# : 1K23AA017689-01A2
Title: "Alcohol Dependence: Pharmacotherapy, Pharmacogenetics, Genetics."
P.I. Albert Arias, M.D.

Percent Effort: 75%
Total Costs for project period: \$730,444
Project Period: 02/01/2010-01/31/2014

Agency: NIAAA
I.D.#: P50 AA03510 – Pilot project funded by UCONN Alcohol Research Center
Title: “Zonisamide Versus Placebo For The Treatment Of Alcohol Dependence”
P.I.: for pilot study- Albert Arias, M.D.
Role on Project: PI
Percent Effort: varied
Total costs for project period: \$60,000
Project period: 10/01/2006-9/31/2009

INVITED SPEAKING ENGAGEMENTS, PRESENTATIONS, SYMPOSIA & WORKSHOPS:

National:

- May, 2022 NIDA Symposium at the American Psychiatric Association annual meeting: Pipe Dreams: The Role of Sleep in the Etiology and Treatment of Substance Use Disorders: The Problem of Insomnia and Addiction: Focus on the Role of the Orexin System.
- Sept, 2016 VA CBOC Tele-Grand Rounds Presentation: Treating Substance Use Disorders in a Community Setting. Tele-broadcast nationally on VA network.
- May, 2007 American Psychiatric Association Annual Meeting, as part of an accredited CME symposium on treating alcohol dependent patients: *Implementing Adherence-Enhancing Strategies in Clinical Practice: Negotiating Within the Therapeutic Alliance*. San Diego, California. Marriott Hotel and Marina.

Regional:

- April, 2022 Medical College of Georgia Department of Psychiatry Grand Rounds: Precision Treatment of AUD with Zonisamide. Discussion of clinical trial results and precision medicine analysis using machine learning and pharmacogenomics.
- Dec, 2021 VCU Psychiatry Grand Rounds (virtual): Precision Treatment of AUD with Zonisamide. Discussion of clinical trial results and precision medicine analysis using machine learning and pharmacogenomics.

- June, 2021 Create Hope: Carilion Research and Experience in Addiction Treatment and Education. Virtual Conference sponsored by Virginia Tech/Carilion. I gave two talks on alcohol use disorder pharmacotherapy. This was aimed at teaching primary care doctors.
- Oct, 2019 VCU Trauma/Critical Care Grand Rounds: Evaluation and Treatment of the Alcohol Withdrawal Syndrome in General and in Critical Care Settings (Including Trauma). VCU Health Main Hospital, Richmond Virginia.
- Oct, 2019 VCU Health Opioid/addiction ECHO teleconference: Incorporating AUD Pharmacotherapy into your Practice: the Basics. VCU Health ECHO telemedicine teleconference suite, Richmond Virginia.
- Sept, 2019 13th Annual Virginia IRB Conference: Special Populations: Recruiting and Researching Subjects with Addictive Disorders. Norfolk, Virginia, Eastern Virginia Medical School Campus.
- Oct, 2018 State of Virginia, DMAS, and Medical Society of Virginia Annual Meeting: 4 hour training symposium for buprenorphine X-waiver training; chair and speaker.
- Aug, 2018 State of Virginia, DMAS, ECHO web broadcast: Benzodiazepine and Stimulant Use with Buprenorphine and Co-occurring Serious Mental Illness.
- Oct, 2017 Medical College of Georgia Department of Psychiatry Grand Rounds: Toward Novel and Personalized Treatments for Alcohol Use Disorder.
- May, 2017 VA CBOC Tele-Presentation for Iron Mountain Michigan Primary Care Retreat: A Practical Approach To Chronic Pain In The Opioid Epidemic Era. Virtual tele-presentation.
- Sept, 2016 Telemental Health: Expanding the Digital Frontier Conference: Special Workshop Breakout Session: Advanced Topics in Telemental Health-Lessons from the Yale/VA National Telehealth Program.
- Oct, 2015 Harlem Hospital Psychiatry Grand Rounds: *Anticonvulsants Treatment of Alcohol Use Disorder*. Harlem (NYC), New York. Harlem Hospital.
- Oct, 2015 Grand Rounds, Connecticut Department of Mental Health and Substance Abuse Services: Bridgeport CMHC: *Toward Novel and Personalized Treatments for Alcohol Use Disorder*. Bridgeport, Connecticut. Bridgeport DMHAS: Greater Bridgeport Community Mental Health Center.
- Feb, 2014 UPENN, Addiction Research and Treatment Center, Invited Speaker: *Toward Novel and Personalized Treatments for Alcohol Use Disorder*. Philadelphia, Pennsylvania. Center for Studies of Addiction.

- June, 2013: Massachusetts Society of Addiction Medicine annual meeting; “2nd annual addiction medicine for all providers: a risk management course.” Lecture: *Managing Alcohol Dependence: an Update and Review of Current Strategies*. Waltham, Massachusetts. Massachusetts Medical Society Building.
- Sept, 2012 Harlem Hospital Psychiatry Grand Rounds: *Pharmacologic Treatment of Alcohol Dependence*. Harlem (NYC), New York. Harlem Hospital.
- March, 2010 Grand Rounds, University of Connecticut School of Medicine, Internal Medicine Department: *Managing Alcohol Dependence in Primary Care*. Farmington, Connecticut. UCONN Health Center.
- June, 2007 UCHC Department of Psychiatry Grand Rounds presentation: *Overview of Treatment Options for the Dually-Diagnosed Alcohol Dependent Patient*. Farmington, Connecticut. UCONN Health Center
- Fall, 2006 UCONN Department of Psychiatry Grand Rounds presentation: *Catatonia*. Farmington, Connecticut. UCONN Health Center
- Fall, 2002 UCONN Department of Psychiatry Grand Rounds: *A Case of Somatization Disorder*. Farmington, Connecticut. UCONN Health Center.

PEER-REVIEWED PRESENTATIONS & SYMPOSIA GIVEN AT MEETINGS:

Symposia and Workshops:

- May, 2019 International Society on Impulsivity Research (InSRI) Annual Meeting: Program Committee co-chair and presenter: *The Dark Side of Impulsivity; Impulsivity as a key dimensional construct of Alcohol Addiction RDoC: Interaction with Anxiety and Aggression*. Hilton Chicago, Chicago, IL.
- July, 2018 Research Society on Marijuana Annual Meeting: Symposium (participant and leader): *Dealing with the frequently comorbid condition of depression and cannabis use disorder in adolescents*. Durrell Center, Colorado State University Campus, Fort Collins, CO.
- June, 2018 Research Society on Alcoholism Annual Meeting Satellite Workshop: *Behavioral Assessment of AUD and Recidivism Risk in Alcohol-related Liver Disease*. Grand Hyatt San Diego, CA.

- Dec, 2017 American Academy of Addiction Psychiatry Annual Meeting: Workshop: *The Virtual Doctor Is In: Integrating Telehealth into Addiction Practice Settings*. Rancho Bernardo Inn San Diego Resort and Conference Center.
- Dec, 2015 American Academy of Addiction Psychiatry Annual Meeting: *Emerging Glutamatergic Treatments for AUD: The Why, Which, and How*. Huntington Beach, California. Hyatt Regency Huntington Beach Resort and Conference Center.
- Dec, 2014 American Academy of Addiction Psychiatry Annual Meeting: Symposium: *Pharmacogenetically driven treatments for substance use disorders*. Chair. Aventura, Florida. Turnberry Isle Resort and Conference Center.
- Dec, 2013 American Academy of Addiction Psychiatry Annual Meeting: Workshop: *Anticonvulsant Treatment of Alcoholism*. Scottsdale, Arizona. Scottsdale Resort and Conference Center.

Paper Presentations:

- Dec, 2021 American Academy of Addiction Psychiatry Annual Meeting: *Zonisamide Treatment of Alcohol Use Disorder*. Virtual Conference Zoom (due to pandemic).
- Dec, 2012 American Academy of Addiction Psychiatry Annual Meeting: *Pharmacogenetics of Naltrexone and Disulfiram in Dually-Diagnosed Alcohol Dependent Veterans*. Aventura, Florida. Turnberry Isle Resort and Conference Center.
- Dec, 2010 American College of Neuropsychopharmacology Annual Meeting: Paper Presentation: *Placebo Controlled Trial of Zonisamide for Alcohol Dependence*. Miami Beach, Florida. Fontainebleau Resort.
- May, 2008 American Psychiatric Institute for Research Education: Research Colloquium for Junior Investigators at the American Psychiatric Association Annual meeting: *Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers*. Washington, D.C.
- Dec, 2005 Annual Meeting of the American Academy of Addiction Psychiatry: *Association of an Asn40Asp (A118G) Polymorphism in the Mu-opioid Receptor Gene with Substance Dependence: A Meta-analysis*. Scottsdale, AZ. Westin Kierland Resort.
- June, 1997 Annual Meeting of the American Association of Neuropathology: *Human mucopolysaccharidosis IIID: Clinical, biochemical, morphological and immunohistochemical characteristics*. Pittsburgh, Pennsylvania.

Poster Presentations:

Dec, 2021, American College of Neuropsychopharmacology Annual meeting: *Zonisamide Treatment of Alcohol Use Disorder*. San Juan Conference Center, San Juan, Puerto Rico.

June 2021, Research Society on Alcoholism Annual Meeting: *Altered Effective Connectivity of the Reward Network During an Incentive Processing Task in Adults with Alcohol Use Disorder*. Virtual Conference (due to pandemic).

Dec, 2020, American College of Neuropsychopharmacology Annual meeting: *Impulsivity, Craving, Stress, and Nighttime Drinking During Treatment for Alcohol Use Disorder (AUD)*. Virtual Conference (due to pandemic).

Dec, 2019, American College of Neuropsychopharmacology Annual meeting: *Neural Correlates of Ethanol-Induced Changes in Aggressive Behavior in Healthy Social Drinkers*. The Hilton Bonnett Creek, Orlando, FL.

Dec, 2018, American College of Neuropsychopharmacology Annual meeting: *The HTR2C Cys23Ser Variant (rs6318) Moderates the Effect of Mirtazapine on Cocaine Attentional Bias and Effective (Directional) Connectivity in Cocaine use Disorder Subjects*. The Diplomat Hollywood, FL.

June 2018, Research Society on Alcoholism Annual Meeting: *Behavioral Assessment of AUD and Recidivism Risk in Alcohol-related Liver Disease*. Grand Hyatt San Diego, CA.

Dec 2017, American College of Neuropsychopharmacology Annual meeting: *Craving Mediates the Effects of a GABRA2 Variant and Naltrexone on Nighttime Drinking*.

June 2016, Research Society on Alcoholism: *GRIK1 SNP rs2832407, Trauma Burden, And Risk For Alcohol Dependence: Results From The National Health And Resilience In Veterans Study*. New Orleans, Louisiana. Hyatt Regency. (Also presented at ACNP and AAAP in December 2016).

June 2015, Research Society on Alcoholism: *Subtypes of Alcoholism in US Military Veterans: A Latent Class Analysis*. San Antonio, Texas. Grand Hyatt.

June 2015, Research Society on Alcoholism: *The Effects Of A GRIK1 Single Nucleotide Polymorphism on The Subjective Response to Intravenous Alcohol Administration*. San Antonio, Texas. Grand Hyatt.

June 2014, Research Society on Alcoholism: *Examining the Relationship Between Depression, Alcohol, and Cannabis Use in Youths in Treatment for a Cannabis Use Disorder*. Bellevue, Washington. Hyatt Hotel.

June 2013, Research Society on Alcoholism: *A GABRA2 variant is Associated with Increased Stimulation and "High" following Alcohol Administration*. Orlando, Florida. Hyatt Regency Grand Cypress.

June 2013, Research Society on Alcoholism: *Pharmacogenetics of Naltrexone and Disulfiram In Dually-Diagnosed Alcohol Dependent Veterans*. Orlando, Florida. Hyatt Regency Grand Cypress.

June 2012, Research Society on Alcoholism: *Effects of Zonisamide Treatment on Short-Term Remission from Alcohol Dependence*. San Francisco, California. Hyatt Regency.

December 2010, American College of Neuropsychopharmacology: *Allelic Association of the GluR5 Kainate Receptor Subunit Gene GRIK1 with Adverse Effects of Topiramate*. Miami Beach, Florida. Fontainebleau Resort.

August 2010, Jackson Laboratory *Short Course on Genetics of Addictions: Lack of an Association of the Human mu-Opioid Receptor Gene OPRM1 Genetic Variants with Suicidal Behavior in a Drug Addicted Population*. Bar Harbor, Maine. Jackson Laboratories Campus.

December 2009, American College of Neuropsychopharmacology: *Zonisamide Versus Placebo in the Treatment of Alcohol Dependence (Final Results)*. Hollywood, Florida. The Diplomat (formerly Westin Diplomat).

June 2009, Research Society on Alcoholism: *Zonisamide Versus Placebo for the Treatment of Alcohol Dependence: Results of a Pilot Study (preliminary results)*. San Diego, California.

June 2008, Research Society on Alcoholism: *Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers*. Washington, D.C. Grand Hyatt.

Dec 2008, Emory University Future Leaders of Psychiatric Annual Conference: *Allelic and Haplotypic Association of the Human mu-Opioid Receptor Gene OPRM1 with Suicidal Behavior; Preliminary Analysis and Future Directions*. Florida.

May 2008, American Psychiatric Institute for Research Education: *Research Colloquium for Junior Investigators at the American Psychiatric Association Annual meeting: Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy Drinkers*.

July 2007, Research Society on Alcoholism Annual Meeting: *Correlates of Co-Occurring ADHD in Drug-Dependent Subjects: Prevalence and Features of Substance Dependence and Psychiatric Disorders*. Chicago, Illinois.

June 2006, Research Society on Alcoholism Annual Meeting: *Open-Label Pilot Study of Memantine for Alcohol Dependence (Final Results)*. Baltimore, Maryland. Hyatt Regency.

Albert J. Arias, M.D., M.S.

Dec 2005, Annual Meeting of the American Academy of Addiction Psychiatry: *Association of an Asn40Asp (A118G) Polymorphism in the Mu-opioid Receptor Gene with Substance Dependence: A Meta-analysis*. Scottsdale, Arizona. Westin Kierland.

Dec 2005, Annual Meeting of the American Academy of Addiction Psychiatry: *Open-Label Pilot Study of Memantine for Alcohol Dependence (Preliminary Results)*. Scottsdale, Arizona. Westin Kierland.

1997, Annual Family Practice Research Day: *Pilot Study of a Behavioral Intervention in Major Depression*. East Lansing, Michigan.

PROFESSIONAL SERVICE

Peer Review Groups/Grant Study Section:

2017-present Member, NIAAA, AA-3 Committee

2017-present (ad hoc) NIAAA special panel, center grant reviews

2016 Ad-hoc member, Scientific Review Group, NIAAA, AA-3 Committee

2013 Ad-hoc member, Special Emphasis Panel/Scientific Review Group, NIAAA

2011 Ad-hoc member, Special Emphasis Panel/Scientific Review Group, NIAAA

2007 Member of review panel for American Institute of Biological Sciences Behavioral Sciences section

Journal Service:

Ad Hoc Reviewer:

2020 Journal of Addiction Medicine

2016-current Alcohol and Alcoholism

2015 The Journal of Studies on Alcohol and Drugs

2013-2014 CNS Drugs

2013 The American Journal of Drug and Alcohol Abuse

2013 Journal of Addiction Research and Therapy

2012 Psychology of Addictive Behaviors

2011-current Neuropsychopharmacology

2010-2016 American Journal on Addictions

2009-2017 Alcoholism: Clinical and Experimental Research

2007-2017 Addiction Biology

2009 Journal of Experimental Psychopharmacology
2008 Alcohol Research and Health
2008 Archives of General Psychiatry
2006 Psychoneuroendocrinology
2006 Social and Personality Psychology Compass

Editorial Board Member:

2011 Frontiers in Psychiatry

Professional Organizations:

American College of Neuropsychopharmacology
2016 Associate Member
2017-2020 Minority Task Force (Diversity) Committee

American Psychiatric Association
2001-2011 Member

American Academy of Addiction Psychiatry
2006-current Member
2011-2013 Member Child and Adolescent Substance Abuse Treatment Committee
2011-2016 Maintenance of Certification Committee
2011-2016 Member, Evidence Based Practice Subcommittee
2018-2020 Member, Research Committee

American Society of Addiction Medicine
2008-2011 Member

International Society for Research on Impulsivity
2019 Member
2019 Program Committee member for annual meeting

Research Society on Alcoholism
2013-current Member
2013, 2015 Program Committee for planning 2014 combined ISBRA/RSA meeting,
also 2016 meeting

Meeting Planning/Participation

2007 Presenter in accredited CME symposium at annual APA meeting; contributed to
planning/course content.

2014 Chair of accredited CME symposium at annual AAAP meeting; contributed to
planning/course content.

University Research Service:

2014-2016 Yale Human Investigations Committee II: member- completed 2 years service

2010-2011 Member, UCONN Health Center Human Investigation Research Adverse Events Committee

BIBLIOGRAPHY

Peer Reviewed Original Research Manuscripts:

1. Jones MZ, Alroy J, Rutledge JC, Taylor JW, Alvord EC, Jr., Toone J, Applegarth D, Hopwood JJ, Skutelsky E, Ianelli C, Thorley-Lawson D, Mitchell-Herpolsheimer C, **Arias A**, Sharp P, Evans W, Sillence D, Cavanagh KT. Human mucopolysaccharidosis IIID: clinical, biochemical, morphological and immunohistochemical characteristics. *J Neuropathol Exp Neurol*. 1997 Oct;56(10):1158-67.
2. **Arias A**, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. *Drug Alcohol Depend*. 2006 Jul 27;83(3):262-8.
3. **Arias AJ**, Feinn R, Covault J, Kranzler HR. Memantine for Alcohol Dependence: An Open-label Pilot Study. *Addictive Disorders & Their Treatment*. 2007 Jun;6(2):77-83
4. Cohen E, Feinn R, **Arias A**, Kranzler HR. Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug Alcohol Depend*. 2007 Jan 12;86(2-3):214-21.
5. Pierucci-Lagha A, Gelernter J, Chan G, **Arias A**, Cubells JF, Farrer L, Kranzler HR. Reliability of DSM-IV diagnostic criteria using the semi-structured assessment for drug dependence and alcoholism (SSADDA). *Drug Alcohol Depend*. 2007 Nov 2;91(1):85-90. PMID: 2039919
6. **Arias AJ**, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Makela R, Kranzler HR. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. *Alcohol Clin Exp Res*. 2008 Jul;32(7):1159-66. PMID: 2950972
7. **Arias AJ**, Gelernter J, Chan G, Weiss RD, Brady KT, Farrer L, Kranzler HR. Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. *Addict Behav*. 2008 Sep;33(9):1199-207. PMID: 2532519
8. Kranzler HR, Covault J, Pierucci-Lagha A, Chan G, Douglas K, **Arias AJ**, Oncken C. Effects of aripiprazole on subjective and physiological responses to alcohol. *Alcohol Clin Exp Res*. 2008 Apr;32(4):573-9. PMID: 3159685

9. Arias JE, Hawke JM, **Arias AJ**, Kaminer Y. Eating Disorder Symptoms and Alcohol Use Among Adolescents in Substance Abuse Treatment. *Substance Abuse: Research and Treatment*. 2009;3:81.
10. Kranzler HR, Gelernter J, Anton RF, **Arias AJ**, Herman A, Zhao H, Burian L, Covault J. Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence. *Alcohol Clin Exp Res*. 2009 May;33(5):925-30. PMID: 2772659
11. Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, **Arias A**, Oncken C. Targeted naltrexone for problem drinkers. *J Clin Psychopharmacol*. 2009 Aug;29(4):350-7. PMID: 3184851
12. Niciu MJ, Chan G, Gelernter J, **Arias AJ**, Douglas K, Weiss R, Anton RF, Farrer L, Cubells JF, Kranzler HR. Subtypes of major depression in substance dependence. *Addiction*. 2009 Oct;104(10):1700-9. PMID: 2980795
13. **Arias AJ**, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. *J Clin Psychopharmacol*. 2010 Jun;30(3):318-22. PMID: 3157084
14. Douglas KR, Chan G, Gelernter J, **Arias AJ**, Anton RF, Weiss RD, Brady K, Poling J, Farrer L, Kranzler HR. Adverse childhood events as risk factors for substance dependence: partial mediation by mood and anxiety disorders. *Addict Behav*. 2010 Jan;35(1):7-13. PMID: 2763992
15. Sherva R, Kranzler HR, Yu Y, Logue MW, Poling J, **Arias AJ**, Anton RF, Oslin D, Farrer LA, Gelernter J. Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. *Neuropsychopharmacology*. 2010 Aug;35(9):1921-31. PMID: 3055642
16. Douglas K, Chan G, Gelernter J, **Arias AJ**, Anton RF, Poling J, Farrer L, Kranzler HR. 5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder. *Psychiatr Genet*. 2011 Oct;21(5):240-8. PMID: 3119731
17. Kranzler HR, Armeli S, Tennen H, Covault J, Feinn R, **Arias AJ**, Pettinati H, Oncken C. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. *J Clin Psychopharmacol*. 2011 Feb;31(1):22-30. PMID: 3130300
18. **Arias AJ**, Chan G, Gelernter J, Farrer L, Kranzler HR. Variation in *OPRM1* and risk of suicidal behavior in drug-dependent individuals. *Am J Addict*. 2012 Jan-Feb;21(1):5-10.
19. Wang F, Simen, A, **Arias A**, Zhang H. A Large-Scale Meta-Analysis of the Association Between the *ANKK1/DRD2* Taq1A Polymorphism and Alcohol Dependence. *Human Genetics*. 2013 Mar;132(3):347-58.
20. Kerfoot K, Pittman B, Ralevski E, Limoncelli D, Koretski J, Newcombe J, **Arias AJ**, Petrakis IL. Effects of family history of alcohol dependence on the subjective response to alcohol using the intravenous alcohol clamp. *Alcoholism: Clinical and Experimental Research*. 2013 Dec;37(12):2011-8. 21.

21. Oncken C, **Arias AJ**, Feinn R, Litt M, Covault J, Sofuoglu M, Kranzler HR. Topiramate for smoking cessation: a randomized, placebo-controlled, pilot study. *Nicotine Tob Res.* 014 Mar;16(3):288-96.
22. Fuehrlein B, Ralevski E, O'Brien E, Jane JS, **Arias AJ**, Petrakis IL. Characteristics and drinking patterns of veterans with alcohol dependence with and without post-traumatic stress disorder. *Addict Behav.* 2014 Feb;39(2):374-8.
23. **Arias AJ**, Covault JM, Feinn R, Pond T, Yang BZ, Wenjing G, Oncken C, Kranzler HR. A *GABRA2* variant is Associated with Increased Stimulation and "High" following Alcohol Administration. *Alcohol and Alcoholism.* 2014 Jan-Feb; 49(1):1-9. PMID: 3865816.
24. Kranzler HR, Covault JM, Feinn R, Armelli S, Tennen H, **Arias AJ**, Gelernter J, Pond T, Oncken C, Kampmann K. Topiramate Treatment of Heavy Drinkers: Moderation by a *GRIK1* Polymorphism. *American Journal of Psychiatry.* Am J Psychiatry 2014; April; 171: 445-452.
25. **Arias AJ**, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of Naltrexone And Disulfiram in Alcohol Dependent, Dually Diagnosed Veterans. *American Journal on Addictions.* 2014: May-Jun; 23(3): 288-93.
26. Covault J, Pond T, Feinn R, **Arias AJ**, Oncken C, Kranzler HR. Dutasteride Reduces Alcohol's Sedative Effects In Men In A Human Laboratory Setting And Reduces Drinking In The Natural Environment. *Psychopharmacology (Berl).* 2014 Sep;231(17):3609-1827.
27. Petrakis IL, Limoncelli D, Desai N, Gueorguieva R, **Arias A**, O'Brien E, Jane J, Sevarino K, Southwick S, Ralevski R. Prazosin for Veterans with Posttraumatic Stress Disorder (PTSD) and Co-Morbid Alcohol Dependence: A Clinical Trial. *Alcoholism: Clinical and Experimental Research.* Addiction. 2016 Apr 9. doi: 10.1111/add.13423. [Epub ahead of print].
28. Fuehrlein BS, Mota N, **Arias AJ**, Trevisan LA, Kachadourian LK, Krystal JH, Southwick SM, Pietrzak RH. The burden of alcohol use disorders in U.S. Military veterans: results from the national health and resilience in veterans study. *Addiction.* 2016 Apr 9. doi:10.1111/add.13423. [Epub ahead of print].
29. Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, **Arias A**, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine Treatment for Alcohol Dependence: A Randomized Controlled Trial. *Addiction.* 2017 Jul 15. doi: 10.1111/add.13943. [Epub ahead of print]. PMID: 28710873
30. Farquharson S, Dana K, Shende C, Gladding Z, Newcomb J, Dascher J, Petrakis IL, **Arias AJ**. Rapid Identification of Buprenorphine in Patient Saliva. 2017. *J Anal Bioanal Tech* 8: 368. PMID: 28944090
31. Manhappa A, **Arias AJ**, Ballantyne JC. The Conundrum of Opioid Tapering in Long-Term Opioid Therapy for Chronic Pain. *Substance Abuse. Subst Abus.* 2017 Sep 20:1-10. doi: 10.1080/08897077.2017.1381663. [Epub ahead of print]
32. *Yang BZ, ***Arias AJ (*co-first authors)**, Feinn R, Krystal J, Gelernter J, Petrakis IL. *GRIK1* and *GABRA2* Variants Have Distinct Effects on the Dose-Related Subjective Response to Intravenous Alcohol in Healthy Social Drinkers. *Alcohol Clin Exp Res.* 2017 Dec;41(12):2025-2032. Epub 2017 Nov 13. PMID: 29131352

33. Broad K, Edens E, **Arias A**, Petrakis I. (2017). The Virtual Doctor Will See You Now: Evaluation of a Pilot Elective in Telemedicine for Addiction Trainees and role of Tele-medical Education in Addiction Fellowship. *International Addiction Review*. 1(1):35-36.
34. Black AC, Cooney NL, Sartor CE, **Arias AJ**, Rosen MI. Impulsivity interacts with momentary PTSD symptom worsening to predict alcohol use in male veterans. *Am J Drug Alcohol Abuse*. 2018 Apr 11:1-8. [Epub ahead of print] PMID:29641264.
35. Petrakis IL, Ralevski E, Gueorguieva R, Sloan M, Devine L, Yoon G, **Arias AJ**, Sofuoglu M. Targeting neuroinflammation with minocycline in heavy drinkers. *Psychopharmacology* (2019). 2019 Mar 27, epub ahead of print. PMID: 30919006
36. Ma L, Steinberg JL, Bjork JM, Taylor BA, **Arias AJ**, Terplan M, Anastasio NC, Zuniga EA, Lennon M, Cunningham KA, Moeller FG. Cingulo-hippocampal effective connectivity positively correlates with drug-cue attentional bias in opioid use disorder. *Psychiatry Res Neuroimaging*. 2019 Aug 13, epub ahead of print. PMID: 31439409
37. **Arias AJ**, Hammond CJ, Burlison JA, Kaminer Y, Feinn R, Curry JF, Dennis ML. Temporal dynamics of the relationship between change in depressive symptoms and cannabis use in adolescents receiving psychosocial treatment for cannabis use disorder. *J Subst Abuse Treat*. 2020 Oct;117:108087. doi: 10.1016/j.jsat.2020.108087. Epub 2020 Jul 20. PubMed PMID: 32811625.
38. Huffstetler AN, Kuzel AJ, Sabo RT, Richards A, Brooks EM, Lail Kashiri P, Villalobos G, **Arias AJ**, Svikis D, Bortz BA, Edwards A, Epling J, Cohen DJ, Parchman ML, Winter J, Wessler P, Yu TJ, Krist AH. Practice facilitation to promote evidence-based screening and management of unhealthy alcohol use in primary care: a practice-level randomized controlled trial. *BMC Fam Pract*. 2020 May 20;21(1):93. doi: 10.1186/s12875-020-01147-4. PubMed PMID: 32434467; PubMed Central PMCID: PMC7240919.
39. Petrakis I, Ralevski E, **Arias AJ**, DeNegre D, Newcomb J, Gianoli M, McCarthy E, Meshberg-Cohen S, Yoon G. Zonisamide as an Adjunctive Treatment to Cognitive Processing Therapy for Veterans With Posttraumatic Stress Disorder and Comorbid Alcohol Use Disorder: A Pilot Study. *Am J Addict*. 2020 May 27;. doi: 10.1111/ajad.13061. [Epub ahead of print] PubMed PMID: 32462773.
40. Hartwell EE, Feinn R, Morris PE, Gelernter J, Krystal J, **Arias AJ**, Hoffman M, Petrakis I, Gueorguieva R, Schacht JP, Oslin D, Anton RF, Kranzler HR. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. *Addiction*. 2020 Aug;115(8):1426-1437. doi: 10.1111/add.14975. Epub 2020 Feb 11. Review. PubMed PMID: 31961981; PubMed Central PMCID: PMC7340566.
41. **Arias AJ**, Ma L, Bjork JM, Hammond CJ, Zhou Y, Snyder A, Moeller FG. Altered effective connectivity of the reward network during an incentive-processing task in adults with alcohol use disorder. *Alcohol Clin Exp Res*. 2021 Jun 12. doi: 10.1111/acer.14650. Online ahead of print. PMID: 34120362
42. Ma L, Cunningham KA, Anastasio NC, Bjork JM, Taylor BA, **Arias AJ**, Riley BP, Snyder AD, Moeller FG. A serotonergic biobehavioral signature differentiates cocaine use disorder

participants administered mirtazapine. *Transl Psychiatry*. 2022 May 6;12(1):187. doi: 10.1038/s41398-022-01934-w. PMID: 35523779; PMCID: PMC9076859.

43. Oliver P, Snyder A, Feinn R, Malov S, McDiarmid G, **Arias AJ**. Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation and generalized anxiety symptoms: A retrospective chart review. *J Clin Psych. In Press*.
44. James, B. , Okonoda, K. , Ebiti, N. , Arias, A. and Koch, J. (2022) Telehealth for Substance Use Disorders Treatment in Nigeria: Implementation Strategies Post-COVID-19. *Open Journal of Psychiatry*, 12, 321-335. doi: 10.4236/ojpsych.2022.124024.
45. Farquharson S, Shende C, Newcomb J, Petrakis IL, Arias AJ. Analysis of Drugs in Saliva of US Military Veterans Treated for Substance Use Disorders Using Supported Liquid Extraction and Surface-Enhanced Raman Spectral Analysis. *Molecules*. 2023 Feb 21;28(5):2010. doi: 10.3390/molecules28052010. PMID: 36903255; PMCID: PMC10004423.

Review Articles, Chapters, Books (all peer reviewed unless noted otherwise):

46. **Arias, A. J.**, Steinberg, K., Banga, A. and Trestman, R. L. Systematic review of the efficacy of meditation techniques as treatments for medical illness. *J Altern Complement Med*. 2006. 12 (8), pp. 817-32.
47. **Arias, A. J.** and Kranzler, H. R. Treatment of co-occurring alcohol and other drug use disorders. *Alcohol Research & Health*. 2008. 31 (2), pp. 155-167.
48. Arias JE, **Arias AJ**, Kaminer Y. Biomarker Testing for Substance Use in Adolescents. *Clinical Manual of Adolescent Substance Abuse Treatment*. 2011. American Psychiatric Press Inc.
49. **Arias A.J.** Sewell A. Pharmacogenetically Driven Treatments for Alcohol Dependence: Are We There Yet? *CNS Drugs*. 2012 Jun 1;26(6):461-76.
50. Niciu M, **Arias AJ**. Targeted Opioid Receptor Antagonists In The Treatment Of Alcohol Use Disorders. *CNS Drugs*. 2013 Oct;27(10):777-87.
51. Hammond C, Niciu M, Drew S, **Arias AJ**. Anticonvulsants for the Treatment of Alcohol Withdrawal Syndrome and Alcohol Use Disorders. *CNS Drugs*. 2015 Apr;29(4):293-311.
52. Jefee-Bahloul H, Jorandby L, **Arias AJ**. Topiramate Treatment of Alcohol Use Disorder in Clinical Practice. *J Addict Med*. 2019 Jan/Feb;13(1):23-27. PMID: 30096078.
53. Manhapra A, Chakraborty A, **Arias AJ**. Topiramate Pharmacotherapy for Alcohol Use Disorder and Other Addictions: A Narrative Review. *J Addict Med*. 2019 Jan/Feb;13(1):7-22. PMID: 30096077.

54. **Arias AJ**, Welch W., Kaminer Y. Bio-Assays and the Detection of Substances of Abuse in Youth. *Clinical Manual of Youth Addictive Disorders*. 2019. American Psychiatric Press Inc.
55. Nishiaoki, M., McNally, D., Bey, R.M., **Arias AJ**. New ACGME-Accredited Addiction Medicine Fellowship Programs and Their Impact on the Field. *Curr Treat Options Psych* **7**, 1–8 (2020).
56. Keen L, **Arias A**, Abbate A, Moeller FG. Heart Rate Variability as a Link Between Brain-Elicited Substance Cues and Substance Use Severity. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2020 Jun;5(6):560-561. doi: 10.1016/j.bpsc.2020.04.010. PMID: 32513390